Current Valuation breakdown for PfizerEnterprise Value is a firm valuation proxy that approximates current market value of a company. It is typically used to determine takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that company has on its balance sheet. When takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Pfizer Current Valuation Assessment
In accordance with recently published financial statements Pfizer Inc has Current Valuation of 208.83 B. This is 829.31% higher than that of Healthcare sector, and 4.27% lower than that of Drug Manufacturers - Major industry, The Current Valuation for all stocks is 623.57% lower than the firm.
Filter other Stocks by Current Valuation
Pfizer Inc is regarded third in current valuation category among related companies. After adjusting for long-term liabilities, total market size of Drug Manufacturers - Major industry is at this time estimated at about 1.49 Trillion. Pfizer retains roughly 208.83 Billion in current valuation claiming about 14% of equities under Drug Manufacturers - Major industry.
Follow Pfizer Current Valuation with Macroaxis syndicated feed, custom widget, or your favorite custom stock ticker
Other Pfizer Fundamentals